Search clinical trials for: Vaccine---primed, CD3/CD28---costimulated autologous peripheral blood T---cells

Total 104 results

Abramson Cancer Center of the University of Pennsylvania

Withdrawn

A Phase-I, Dose Escalation Study of Recombinant Human Interleukin-18 (Sb-485232) Combined With Adoptive Transfer of Vaccine-Primed CD3/CD28-Costimulated Autologous T-Cells Following Lymphodepletion for Adult Patients With Recurrent Ovarian, Fallopian Tube or Primary Peritoneal Cancer

Ovarian, Fallopian Tube and Peritoneal Cancer

United States
University of Pennsylvania

Completed

Umbilical Cord Blood Transplant for Hematological Malignancies (UCB)

Multiple Myeloma | AML | MDS | NHL | CML | Hodgkin's Disease | ALL

United States
University of Pennsylvania
M.D. Anderson Cancer Center

Completed

CD3/CD28 Bead Activated T-Cells Following Chemo-Immunotherapy in Patients With Chronic Lymphocytic Leukemia

Chronic Lymphocytic Leukemia

United States
Nantes University Hospital

Completed

Study of the Frequency and of the Regulatory Function of Positive T Lymphocytes Dual CD4CD8aa (DP8a) Specific to a Bacteria of the Intestinal Microbiota (Faecalibacterium Prausnitzii) in Atopic Dermatitis, Asthma and Allergic Rhinitis (Prévall-DP)

Allergic Rhinitis | Atopic Dermatitis | Allergic Asthma

France
Masonic Cancer Center, University of Minnesota

Terminated

Donor T Cells in Treating Patients With High-Risk Hematologic Cancer Undergoing Donor Peripheral Blood Stem Cell Transplant

Lymphoma | Myelodysplastic Syndromes | Leukemia | Multiple Myeloma and Plasma Cell Neoplasm | Graft Versus Host Disease

United States
Barbara Ann Karmanos Cancer Institute
National Cancer Institute (NCI)

Completed

Treated T Cells Followed by a Stem Cell Transplant in Treating Patients With Multiple Myeloma

Multiple Myeloma and Plasma Cell Neoplasm

United States
T-knife GmbH

Terminated

A Phase 1/ 2, First-in-Human, Open-Label, Accelerated-Titration, Two-Part Clinical Trial of TK-8001 in Patients With HLA-A*02:01 Genotype and Advanced-Stage/ Metastatic MAGE-A1+ Solid Tumors (IMAG1NE)

Advanced Solid Tumors

Germany, Belgium, Spain, Netherlands, United Kingdom
National Institute of Allergy and Infectious Diseases...
Autoimmunity Centers of Excellence

Terminated

Autologous Polyclonal Tregs for Lupus

Lupus Erythematosus, Systemic | Lupus Erythematosus, Cutaneous | Lupus Erythematosus, Discoid

United States
Shanghai Zhongshan Hospital

Unknown

Purified CD34+ Cells Versus Peripheral Blood Mononuclear Cells in Treatment of Critical Limb Ischemia

Peripheral Arterial Disease | Arteritis | Thromboangiitis Obliterans

China
Abramson Cancer Center of the University of Pennsylvania

Terminated

Autologous T-Cells Combined With Autologous OC-DC Vaccine in Ovarian Cancer

Fallopian Tube Cancer | Primary Peritoneal Cancer | Ovarian Carcinoma

United States
University of Alberta
Juvenile Diabetes Research Foundation; Diabetes Research Institute Foundation; Alberta Diabetes Institute and other collaborators

Active, not recruiting

PolyTreg Immunotherapy in Islet Transplantation

Diabetes | Diabetes Mellitus, Type 1

Canada
Medical College of Wisconsin
Midwest Athletes Against Childhood Cancer

Not yet recruiting

CD30biAb-AATC for CD30+ Malignancies

Lymphoma | Leukemia | Hodgkin Disease | CD30-Positive Diffuse Large B-Cell Lymphoma | CD30+ Anaplastic Large Cell Lymphoma | CD30+ Pleomorphic Large T-Cell Cutaneous Lymphoma | CD30+ Immunoblastic Large T-Cell Cutaneous Lymphoma

United States
Foundation for Biomedical Research and Innovation
Institute of Biomedical Research and Innovation, Kobe, Hyogo, Japan; Kobe City... and other collaborators

Terminated

Stem Cell Study for Patients With Heart Disease

Myocardial Infarction | Coronary Artery Disease | Chest Pain | Angina | Chronic Myocardial Ischemia

Japan
Translational Research Center for Medical Innovation...
Institute of Biomedical Research and Innovation, Kobe, Hyogo, Japan; Kobe City...

Completed

Stem Cell Study for Patients With Leg Ulcer/Gangrene

Ischemia | Ulcer | Peripheral Vascular Diseases | Gangrene | Leg Pain

Japan
Ronald Levy
National Institutes of Health (NIH)

Completed

Phase 1-2 of a CpG-Activated Whole Cell Vaccine Followed by Autologous Immunotransplant for MCL

Lymphoma, Mantle-Cell

United States
Fred Hutchinson Cancer Center
National Cancer Institute (NCI); Juno Therapeutics, Inc.

Completed

Immunotherapy With BCMA CAR-T Cells in Treating Patients With BCMA Positive Relapsed or Refractory Multiple Myeloma

Refractory Plasma Cell Myeloma | Recurrent Plasma Cell Myeloma

United States
Sidney Kimmel Comprehensive Cancer Center at Johns...
National Cancer Institute (NCI)

Terminated

Vaccine Therapy With or Without Donor Lymphocyte Infusion in Treating Patients With Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, or Multiple Myeloma Undergoing Donor Stem Cell Transplant

Leukemia | Multiple Myeloma and Plasma Cell Neoplasm

United States
Imcyse SA

Terminated

A Trial for Evaluating Both Safety and Preliminary Efficacy of a Single Infusion of Stimulated Autologous CD4+T Cells in Patients With Relapsing- Remitting Multiple Sclerosis (SCLEROLYM)

Multiple Sclerosis, Relapsing-Remitting

Belgium
Prof. Dr. Petra Reinke

Completed

The ONE Study nTreg Trial (ONEnTreg13) (ONEnTreg13)

Immunosuppressive Treatment of Living-donor Renal Transplantation

Germany
M.D. Anderson Cancer Center
Ziopharm Oncology

Terminated

CD19-Specific T Cells Post AlloSCT

Recurrent Mantle Cell Lymphoma | Recurrent Small Lymphocytic Lymphoma | Recurrent B Acute Lymphoblastic Leukemia | Recurrent Diffuse Large B-Cell Lymphoma, Not Otherwise Specified | Refractory B Acute Lymphoblastic Leukemia | Refractory Diffuse Large B-Cell Lymphoma, Not Otherwise Specified | Refractory... and other conditions

United States
Barbara Ann Karmanos Cancer Institute
National Cancer Institute (NCI)

Withdrawn

Donor T Cells, Low-Dose Aldesleukin, and Low-Dose GM-CSF After Donor Stem Cell Transplant in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma

Lymphoma
Fred Hutchinson Cancer Center
National Cancer Institute (NCI); Affini-T Therapeutics, Inc.

Active, not recruiting

Gene-Modified Immune Cells (FH-MCVA2TCR) in Treating Patients With Metastatic or Unresectable Merkel Cell Cancer

Other Skin

United States
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Completed

T-Cell Infusion, Aldesleukin, and Utomilumab in Treating Patients With Recurrent Ovarian Cancer

Recurrent Ovarian Carcinoma | HLA-A*0201 Positive Cells Present | COL6A3 Positive | PRAME Positive

United States
daphne brockington

Unknown

Continuous Alloreactive T Cell Depletion and Regulatory T Cell Expansion for the Treatment of Steroid-refractory or Dependent Chronic GVHD (CARE)

Chronic GVHD After HCT for Cancer or Immune Disease

Canada
University of Pennsylvania

Completed

Combination Immunotherapy and Autologous Stem Cell Transplantation for Myeloma

Myeloma

United States
Fundacion Clinic per a la Recerca Biomédica

Not yet recruiting

First in Human Study of the Infusion of ARI0003 Cells in Relapsed/Refractory to Treatment B-cell Aggressive Lymphoma (CARTD-BG-1)

Refractory Non-Hodgkin Lymphoma | Relapsed Non-Hodgkin Lymphoma

Spain
M.D. Anderson Cancer Center

Recruiting

Cytokine-Treated Veto Cells in Treating Patients With Hematologic Malignancies Following Stem Cell Transplant

Follicular Lymphoma | Acute Myeloid Leukemia | Hodgkin Lymphoma | Acute Lymphoblastic Leukemia | Mantle Cell Lymphoma | Chronic Lymphocytic Leukemia | Non-Hodgkin Lymphoma | Myelodysplastic Syndrome | Plasma Cell Myeloma | Aplastic Anemia | Myeloproliferative Neoplasm | Bone Marrow Failure | Chronic Myelogenous...

United States
National Cancer Institute (NCI)

Active, not recruiting

Lenalidomide in Treating Patients With Multiple Myeloma Undergoing Autologous Stem Cell Transplant

Smoldering Multiple Myeloma | Refractory Multiple Myeloma | DS Stage I Multiple Myeloma | DS Stage II Multiple Myeloma | DS Stage III Multiple Myeloma

United States
Fred Hutchinson Cancer Center
Juno Therapeutics, Inc., a Bristol-Myers Squibb Company

Terminated

huJCAR014 CAR-T Cells in Treating Adult Patients With Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma or Acute Lymphoblastic Leukemia

Refractory B-Cell Non-Hodgkin Lymphoma | Recurrent Adult Acute Lymphoblastic Leukemia | Recurrent B-Cell Non-Hodgkin Lymphoma | Recurrent Diffuse Large B-Cell Lymphoma | Recurrent Primary Mediastinal (Thymic) Large B-Cell Lymphoma | Refractory Adult Acute Lymphoblastic Leukemia | Refractory Diffuse... and other conditions

United States
University of Nebraska

Terminated

Enhancing Anti--Tetanus Vaccine Response After Autologous Stem Cell Transplantation

Plasma Cell Myeloma

United States
Fred Hutchinson Cancer Center
SignalOne Bio, Inc.

Terminated

Genetically Engineered Cells (MAGE-A1-specific T Cell Receptor-transduced Autologous T-cells) and Atezolizumab for the Treatment of Metastatic Triple Negative Breast Cancer, Urothelial Cancer, or Non-small Cell Lung Cancer

Metastatic Lung Non-Small Cell Carcinoma | Anatomic Stage IV Breast Cancer AJCC v8 | Stage IV Lung Cancer AJCC v8 | Metastatic Malignant Solid Neoplasm | Metastatic Urothelial Carcinoma | Metastatic Triple-Negative Breast Carcinoma

United States
National Cancer Institute (NCI)

Terminated

Anti-MART-1 F5 Lymphocytes to Treat High-Risk Melanoma Patients

Melanoma

United States
Fred Hutchinson Cancer Center
National Cancer Institute (NCI)

Completed

Vaccine Therapy Following Therapeutic Autologous Lymphocytes and Cyclophosphamide in Treating Patients With Metastatic Melanoma

Recurrent Melanoma | Stage IV Melanoma

United States
Sidney Kimmel Comprehensive Cancer Center at Johns...
PapiVax Biotech, Inc.

Recruiting

Safety and Efficacy of Allogeneic HPV-specific T Cells in Adults With Recurrent or Metastatic HPV16+ Cancers

HPV 16+ Recurrent or Metastatic Cancer

United States
Grupo Cooperativo de Estudio y Tratamiento de las...

Completed

Risk Adapted Treatment for Primary Acute Myeloid Leukemia (AML)

Leukemia, Myelocytic, Acute

Spain
National Cancer Institute (NCI)

Completed

APC8015 and Bevacizumab in Treating Patients With Prostate Cancer

Prostate Cancer

United States
National Cancer Institute (NCI)

Terminated

p53 Vaccine for Ovarian Cancer

Ovarian Neoplasm

United States
City of Hope Medical Center
National Cancer Institute (NCI)

Active, not recruiting

Genetically Engineered Lymphocyte Therapy After Peripheral Blood Stem Cell Transplant in Treating Patients With High-Risk, Intermediate-Grade, B-cell Non-Hodgkin Lymphoma

Recurrent Grade 1 Follicular Lymphoma | Recurrent Grade 2 Follicular Lymphoma | Recurrent Grade 3 Follicular Lymphoma | Recurrent Mantle Cell Lymphoma | Recurrent Non-Hodgkin Lymphoma

United States
Fred Hutchinson Cancer Center
National Cancer Institute (NCI); National Institutes of Health (NIH)

Withdrawn

Radioimmunotherapy (211At-OKT10-B10) and Chemotherapy (Melphalan) Before Stem Cell Transplantation for the Treatment of Multiple Myeloma

Plasma Cell Myeloma

United States
Barbara Ann Karmanos Cancer Institute
National Cancer Institute (NCI)

Withdrawn

Activated T-cell Therapy, Low-Dose Aldesleukin, and Sargramostim in Treating Patients With Ovarian, Fallopian Tube, or Primary Peritoneal Cancer That is Stage III-IV, Refractory, or Recurrent

Recurrent Fallopian Tube Carcinoma | Recurrent Ovarian Carcinoma | Recurrent Primary Peritoneal Carcinoma | Malignant Ovarian Clear Cell Tumor | Stage IIIA Fallopian Tube Cancer | Stage IIIA Ovarian Cancer | Stage IIIA Primary Peritoneal Cancer | Stage IIIB Fallopian Tube Cancer | Stage IIIB Ovarian... and other conditions
Guenther Koehne

Suspended

CD34+ Enriched Transplants to Treat Myelodysplastic Syndrome

Myelodysplastic Syndromes | Graft Vs Host Disease | Graft-versus-host-disease

United States
SWOG Cancer Research Network
National Cancer Institute (NCI); Genentech, Inc.

Recruiting

Testing Drug Treatments After CAR T-cell Therapy in Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma

Diffuse Large B-Cell Lymphoma | Recurrent Diffuse Large B-Cell Lymphoma | Refractory Diffuse Large B-Cell Lymphoma | Primary Mediastinal (Thymic) Large B-Cell Lymphoma | Grade 3b Follicular Lymphoma | Transformed Follic Lymph to Diff Large B-Cell Lymphoma | Transformed Marg Zone Lymph to Diff...

United States
Fred Hutchinson Cancer Center
National Cancer Institute (NCI); AstraZeneca; Juno Therapeutics, Inc.; MedImmune...

Terminated

JCAR014 and Durvalumab in Treating Patients With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma

Recurrent Diffuse Large B-Cell Lymphoma | Recurrent Primary Mediastinal (Thymic) Large B-Cell Lymphoma | Refractory Diffuse Large B-Cell Lymphoma | Refractory Primary Mediastinal (Thymic) Large B-Cell Lymphoma | Refractory High Grade B-Cell Lymphoma With MYC, BCL2, and BCL6 Rearrangements | Diffuse Large B-Cell Lymphoma, Not Otherwise Specified

United States
University of Maryland, Baltimore
University of Maryland Greenebaum Cancer Center

Completed

Chemotherapy and Peripheral Stem Cell Transplantation Followed By Immunotherapy in Treating Patients With Multiple Myeloma

Infection | Multiple Myeloma and Plasma Cell Neoplasm

United States
Dana-Farber Cancer Institute

Recruiting

IS-free Treg HaploHCT

Myelodysplastic Syndromes | Graft Vs Host Disease | Stem Cell Transplant Complications | Myeloid Leukemia, Acute | Myeloid Leukemia in Relapse (Disorder)

United States
Robert Lowsky
National Cancer Institute (NCI)

Completed

CD8+ Memory T-Cells as Consolidative Therapy After Donor Non-myeloablative Hematopoietic Cell Transplant in Treating Patients With Leukemia or Lymphoma

Acute Myeloid Leukemia | Hodgkin Lymphoma | Chronic Lymphocytic Leukemia | Myelodysplastic Syndrome | B-Cell Non-Hodgkin Lymphoma | Myeloproliferative Neoplasm | T-Cell Non-Hodgkin Lymphoma

United States
National Cancer Institute (NCI)

Terminated

Vaccine Therapy With or Without Interleukin-2 After Chemotherapy and an Autologous White Blood Cell Infusion in Treating Patients With Metastatic Melanoma

Recurrent Melanoma | Stage IV Melanoma

United States
National Cancer Institute (NCI)

Terminated

Phase II Study of Metastatic Melanoma With Lymphodepleting Conditioning and Anti-gp100:154-162 TCR Gene Engineered Lymphocytes

Melanoma | Skin Cancer

United States
National Institutes of Health Clinical Center (CC)
National Cancer Institute (NCI)

Terminated

Gene-Modified Lymphocytes, High-Dose Aldesleukin, and Vaccine Therapy in Treating Patients With Progressive or Recurrent Metastatic Cancer

Kidney Cancer | Unspecified Adult Solid Tumor, Protocol Specific | Melanoma (Skin)

United States
Barbara Ann Karmanos Cancer Institute
National Cancer Institute (NCI)

Completed

Chemotherapy and Vaccine Therapy Followed by Bone Marrow or Peripheral Stem Cell Transplantation and Interleukin-2 in Treating Patients With Recurrent or Refractory Brain Cancer

Brain and Central Nervous System Tumors

United States

Search clinical trials for: Vaccine---primed, CD3/CD28---costimulated autologous peripheral blood T---cells

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Pakistan

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations